From the Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylania 19104
Received for publication, December 20, 2002
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Growth factor receptors promote cell
growth and survival by stimulating the activities of
phosphatidylinositol 3-kinase and Akt/PKB. Here we report that
Akt activation causes proteasomal degradation of substrates that
control cell growth and survival. Expression of activated Akt triggered
proteasome-dependent declines in the protein levels of the
Akt substrates tuberin, FOXO1, and FOXO3a. The addition of proteasome
inhibitors stabilized the phosphorylated forms of multiple Akt
substrates, including tuberin and FOXO proteins. Activation of Akt
triggered the ubiquitination of several proteins containing
phosphorylated Akt substrate motifs. Together the data indicate that
activated Akt stimulates proteasomal degradation of its substrates and
suggest that Akt-dependent cell growth and survival are
induced through the degradation of negative regulators of these processes.
Metazoan cell size, survival, and proliferation are coordinately
regulated by the availability of extrinsic growth factors that govern
these processes through their control of intracellular signal
transduction cascades. The signals emanating from growth factor
receptors determine the size, number, and turnover rate of cells within
a given tissue (1). A major pathway that controls cell growth and
survival in response to the activation of growth factor receptors is
the phosphatidylinositol 3-kinase/Akt
(PI3K1/Akt) pathway (2).
Studies of the PI3K/Akt pathway in model organisms such as
Drosophila melanogaster and Caenorhabditis
elegans have established the importance of this pathway in
controlling the number and size of cells within an organism and also in
controlling the size and longevity of the entire organism. In
vertebrates, constitutively active oncogenic forms of both PI3K and Akt
have been characterized in murine and avian retroviruses, and
inactivating mutations in PTEN (a phosphatase that opposes
the action of PI3K) are prevalent in many types of human tumors
(3-5).
Activation of the PI3K/Akt pathway stimulates growth and survival via
its actions on a number of Akt substrates, including the FOXO family
transcription factors Bad, GSK-3, mTOR, and tuberin. Active FOXO
family transcription factors promote the transcription of genes
involved in cell cycle arrest and apoptosis such as
p27kip1 and Bim (6-8). One mechanism by which Akt
promotes cell survival is by phosphorylating FOXO family transcription
factors, which inactivates them and prevents the transcription of
proapoptotic molecules. Recently Akt has also been shown to
phosphorylate and inactivate a negative regulator of cell size, tuberin
(9-12). In conjunction with its binding partner hamartin, increased
tuberin protein levels negatively regulate cell size, possibly by
inhibiting the phosphorylation and activation of mTOR or
p70S6K. Phosphorylation by Akt prevents
tuberin-dependent declines in cell size.
In growth factor-dependent cells, the removal of growth
factors triggers cellular atrophy and the initiation of programmed cell
death (13). Activation of Akt inhibits both of these processes, suggesting that Akt can inhibit mediators of both cell atrophy and cell
death (14). In analyzing the effects of Akt activation on downstream
targets involved in the regulation of cell size and survival, we show
here that the activation of Akt results in a decline in total protein
levels of tuberin and FOXO3a. The Akt-stimulated decline in tuberin
correlated with a decline in the protein level of its binding partner,
hamartin, suggesting that the tuberin-hamartin complex is coordinately
regulated by Akt. Inhibition of the proteasome resulted in a recovery
in the protein levels of tuberin, FOXO1, and FOXO3a and triggered a
general accumulation of Akt substrates. Physiologic activation of the endogenous PI3K/Akt pathway through the IL-3 receptor in the presence of proteasome inhibitors resulted in prolonged phosphorylation of
tuberin and FOXO3a. IL-3 stimulation triggered the ubiquitination of a
number of potential Akt substrates, indicating that
Akt-dependent degradation of substrates may be induced
through their ubiquitination. Together the data indicate that
activation of Akt targets the substrates of Akt for degradation in the proteasome.
Cell Lines and Culture
Conditions--
IL-3-dependent FL5.12 cells were cultured
in 350 pg/ml recombinant murine IL-3 (R&D Systems) as described
previously (15). Vector control and myristoylated Akt
(myrAkt)-expressing cells were transduced with either empty pRevTRE
retroviral vector (BD Clontech) or myrAkt pRevTRE,
as described previously (14). Bcl-xL was expressed in cells
with pSFFV-Bcl-xL, also described previously (16). FOXO1
and FOXO1-3A, generously provided by Drs. Fred Barr (University of
Pennsylvania) and Gabriel Nunez (University of Michigan) were cloned
into pRevTRE and transduced into an FL5.12 line that carries the
rtTA transcriptional activator of tetracycline-regulated promoters (17). Clones were selected by immunoblot for the ability to
induce FOXO1 and FOXO1-3A protein expression to comparable levels. For
regular passage, all cell lines were cultured in the absence of
doxycycline. For induction of myrAkt, doxycycline was added to the
medium (1 µg/ml, BD Clontech) for 24 h
followed by an additional 48 h of culture in
doxycycline-supplemented medium with or without IL-3 as appropriate.
Bcl-xL-expressing and vector control lines were treated
similarly to control for nonspecific effects of doxycycline unless
otherwise indicated. Induction of FOXO1 constructs was for 24 h
before lysis. Measurement of cellular viability was performed by flow
cytometric analysis of cells stained in phosphate-buffered saline
containing 2 µg/ml propidium iodide.
IL-3 Stimulation--
FL5.12 cells were withdrawn from IL-3 for
4 h, pelleted, and resuspended in medium lacking IL-3 at a density
of 1 × 107/ml. Vehicle control
Me2SO or 100 nM final concentration
epoxomicin was added, and cells were preincubated at 37 °C for 30 min. Recombinant murine IL-3 was added to a final concentration of 4 ng/ml, and each sample was incubated at 37 °C for the indicated
time. After each incubation, cells were pelleted for 30 s and
directly lysed in ice-cold radioimmune precipitation buffer as
described above. Cell lysates were kept on ice until the end of the
experiment, and equal quantities of protein were resolved by gel
electrophoresis without freezing.
Cell Size Measurements--
Cell size was assessed in live cells
incubated with 10 µg/ml cell-permeant DNA dye, Hoechst 33342, for 30 min at 37 °C and 2 µg/ml propidium iodide. After analysis by flow
cytometry (LSR instrument, BD Biosciences), the forward scatter
of G1-phase live cells was plotted for vector control,
Bcl-xL-expressing, and myrAkt-expressing cells.
Cell Lysis and Immunoblots--
Cells were washed once in
phosphate-buffered saline before lysis in ice-cold radioimmune
precipitation buffer containing protease inhibitors (Complete Mini,
Roche Molecular Biochemicals) and phosphatase inhibitors (10 mM sodium fluoride, 250 µM sodium
orthovanadate, and 20 mM sodium Proteasome Inhibitors and Analysis of Ubiquitin
Conjugates--
ALLN and ALLM (Calbiochem) dissolved in
Me2SO were added to final concentrations of 50 µM; epoxomicin (Calbiochem) dissolved in
Me2SO was added to a final concentration of 100 nM. Vehicle control Me2SO was added to cells
that were not treated with proteasome inhibitors. Cells that had been
incubated in the presence of proteasome inhibitors were lysed in
ice-cold NET-N (10 mM Tris, pH 8.0, 5 mM
EDTA, 150 mM NaCl, and 1% Nonidet P-40) containing
protease inhibitors and phosphatase inhibitors (10 mM
sodium fluoride, 250 µM sodium orthovanadate, and 20 mM sodium Stable transfectants expressing constitutively active myrAkt under
the control of a tetracycline-responsive promoter were established
using the nontransformed IL-3-dependent murine
hematopoietic cell line FL5.12 with the intent of identifying and
purifying Akt substrates involved in the control of growth and survival (Fig. 1, A and B).
A low level of myrAkt is expressed in the absence of doxycycline.
However, the addition of doxycycline to myrAkt-expressing cells results
in a rapid and prolonged increase in Akt activity with concomitant
increases in cell size and the induction of growth factor-independent
cell survival (Fig. 1C). Disappointingly, using antibodies
specific for Akt phosphorylation sites, doxycycline induction of Akt
failed to induce an increase in the number or intensity of
immunoreactive bands on immunoblots. This result prompted an
examination of the expression of specific Akt substrates. The Akt
consensus phosphorylation sequence identified tuberin as a potential
Akt substrate, which has been confirmed recently in several studies (9,
11, 18, 19). Analysis of tuberin expression revealed a decline in
tuberin protein levels as Akt activity was induced (Fig.
1D). A decline in the protein levels of the tuberin binding
partner hamartin was also observed in myrAkt cells, and this decline
was consistently accompanied by the appearance of a faster migrating
species in hamartin immunoblots, suggesting the generation of a
hamartin degradation product in cells with activated Akt.
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
-glycerophosphate;
Sigma). Lysates were sonicated for 5 s, and insoluble matter was
removed by centrifugation. Cell extracts were standardized for protein
content using the BCA protein assay (Pierce), and 25 µg of total cell
extract was loaded per lane. Proteins were resolved on Tris acetate
3-8% gradient gels (Invitrogen) and transferred to nitrocellulose for
immunoblotting. Anti-tuberin C20, anti-FOXO3a H144, anti-human FOXO1
H128, anti-actin I18, and anti-ubiquitin P4D1 were obtained from Santa
Cruz; anti-hamartin 2-8a was a kind gift of Dr. Jeff E. DeClue
(National Cancer Institute, Bethesda, MD); anti-Akt, anti-Akt pS473,
anti-murine FOXO1, anti-Akt substrates, anti-FOXO3a pT26, and
anti-tuberin pT1462 were obtained from Cell Signaling Technology.
Quantitation of immunoblot data was performed using ImageQuant
(Amersham Biosciences).
-glycerophosphate; Sigma).
N-ethylmaleimide (freshly prepared as a 1 M
stock in 100% EtOH) was added immediately after lysis to a final
concentration of 10 mM. Lysates were then sonicated for
5 s, and insoluble matter was removed by centrifugation. Lysates
were standardized for protein content, and 500 µg of total protein
were tumbled with 40 µl of agarose beads bound to the UBA domains
from Rad23 (Ubiquitinated Protein Enrichment Kit, Calbiochem) for 2-4
h at 4 °C. After the beads were washed three times in lysis buffer,
PAGE sample buffer was added, and the beads were incubated for 5 min at 95 °C. Bound proteins were resolved by gel
electrophoresis and probed by immunoblot.
RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
View larger version (26K):
[in a new window]
Fig. 1.
Akt activation triggers declines in
tuberin and hamartin protein levels. A, activated Akt was
expressed under the control of a tetracycline-responsive promoter in
FL5.12 cells. Doxycycline (Dox), a tetracycline analogue,
was added to vector control (V) and myrAkt (A)
cultures during a 3-day time period, and expression of activated Akt
was assessed in immunoblots for phosphorylated Akt serine 473 (p-Akt) or total Akt. An actin immunoblot is included as a
loading control. B, quantitative analysis of the immunoblot
of phospho-Akt standardized to the immunoblot of actin for vector
control (Vec.) and myrAkt-expressing cells (Akt).
Data are presented as the -fold induction of phosphorylated Akt.
C, vector control and cells expressing activated Akt were
cultured in the absence of IL-3 for 48 h. Viability was assessed
in triplicate by measuring propidium iodide exclusion in a flow
cytometer. D, vector control, Bcl-xL-expressing
(XL), and activated Akt-expressing cells were
cultured for 3 days in the presence or absence of doxycycline as
indicated, and total cell lysates were prepared for analysis in
tuberin, hamartin, and actin immunoblots. Results are representative of
three similar experiments. E, after preincubation in the
presence or absence of doxycycline as indicated, Bcl-xL-
and myrAkt-expressing cells were cultured for an additional 2 days in
the absence of IL-3. Note that vector control cells are no longer
viable at this time point. Total cell lysates were analyzed in tuberin,
hamartin, and actin immunoblots. Results are representative of at least
three similar experiments. F, vector control
(Ctrl., blue) and myrAkt (red) cells
cultured in IL-3 and doxycycline were stained with propidium iodide and
the cell-permeant DNA dye Hoechst 33342. Forward scatter was assessed
by flow cytometry, and the cell size of G1-phase live cells
is plotted. Mean forward scatter for vector control cells and myrAkt
cells was 441 and 506, respectively. G, Bcl-xL
(Ctrl., blue) and myrAkt (red) cells
were cultured, stained, and analyzed as in panel
F, except cells were cultured in the absence of IL-3 for 2 days. Mean forward scatter for Bcl-xL and myrAkt cells was
254 and 301, respectively.
In IL-3-dependent cells, growth factor withdrawal rapidly induces a decline in cell size followed by the induction of programmed cell death. Expression of Bcl-xL prevents the induction of cell death without altering the kinetics of cell atrophy, permitting analysis of cell atrophy in the absence of complicating effects of apoptosis (13). Because tuberin and hamartin function in complex to negatively regulate cell size (20-23), we compared the effect of IL-3 withdrawal and the induction of atrophy on tuberin and hamartin protein expression levels in Bcl-xL-expressing and myrAkt-expressing cells. IL-3 withdrawal had little effect on tuberin and hamartin protein levels. However, induction of Akt in the absence of other components of IL-3 signal transduction still led to a near complete decline in both hamartin and tuberin levels (Fig. 1E). The declines in tuberin and hamartin levels in cells with activated Akt corresponded with increased cell size both in the presence and absence of IL-3 (Fig. 1, F and G).
Phosphorylation can target proteins for degradation by the proteasome
(24). To determine whether proteasomal degradation was involved in the
decline in tuberin protein levels in myrAkt-expressing cells, the
proteasome inhibitor ALLN was added to cultures. In vector control and
Bcl-xL-expressing cells, the addition of ALLN had little
effect on tuberin protein levels. However, ALLN triggered a substantial
recovery of tuberin protein in myrAkt-expressing cells, suggesting that
proteasomal degradation of tuberin was triggered by activated Akt (Fig.
2A). In addition to inhibiting proteasomal degradation, ALLN inhibits the activities of other proteases within the cell. To verify the involvement of the proteasome in the Akt-dependent decline in tuberin levels, cells were
treated with ALLM, an analogue of ALLN that shares the ability to
inhibit proteases but has poor affinity for the proteasome (25). In contrast to ALLN, ALLM treatment did not result in the recovery of
tuberin protein levels, indicating that the ability to inhibit the
proteasome is required to prevent degradation of tuberin (Fig. 2B). Further evidence supporting a role for the proteasome
in Akt-dependent declines in tuberin levels was obtained by
treating cells with epoxomicin, an irreversible inhibitor of the
proteasome with a mechanism of action that is distinct from ALLN (26). Similar to ALLN, the addition of epoxomicin to Akt-expressing cells
resulted in a recovery in tuberin protein levels (Fig. 2B). Thus, Akt stimulates proteasomal degradation of tuberin.
|
Akt can phosphorylate tuberin in vitro and in
vivo at a number of sites, suggesting that Akt might trigger
tuberin degradation by phosphorylation (9, 11). To determine whether
other Akt substrates are also targeted for degradation by the
proteasome, vector control, Bcl-xL-expressing, and
myrAkt-expressing cells were treated with ALLN and probed in an
immunoblot with an antiserum specific for phosphorylated residues in
the context of the consensus Akt substrate motif (9). Surprisingly, the
number of immunoreactive protein species was lower in Akt-expressing
cells than in control or Bcl-xL-expressing cells. However,
a number of bands containing potential Akt phosphorylation sites were
induced by treatment with ALLN in all three lines, and the magnitude of
induction was greatest in cells expressing activated Akt (Fig.
3A). The accumulation of Akt
substrates in control cells cultured in ALLN and IL-3 suggests that the
IL-3 receptor activation of the endogenous PI3K/Akt pathway is
sufficient to cause degradation of Akt substrates. These data suggest
that Akt may target a number of substrates for proteasomal degradation,
and the extent of proteasomal degradation correlates with the extent of
Akt activation.
|
Because ALLN promoted the accumulation of potential Akt substrates in the 50-90-kDa range, the effects of proteasome inhibitors on protein levels of FOXO family transcription factors were evaluated as a test of this hypothesis. Expression of activated Akt triggered a decline in protein levels of both FOXO1 and FOXO3a, and treatment of cells with ALLN triggered a recovery in protein levels for both transcription factors (Fig. 3B). In lysates from vector control cells the addition of ALLN triggered a significant increase in FOXO3a protein levels, specifically in a slower migrating form of the protein. This result suggested that IL-3 receptor stimulation was sufficient to trigger endogenous Akt phosphorylation and degradation of FOXO3a. To test this possibility, vector control and myrAkt cells were cultured in the presence and absence of ALLN and the PI3K inhibitor LY294002. As shown previously, culture in the presence of ALLN caused an accumulation of a slow migrating form of FOXO3a. The addition of LY294002 prevented IL-3-induced phosphorylation of FOXO3a and caused an increase in the mobility of total FOXO3a protein (Fig. 3C). The addition of LY294002 had little effect on the phosphorylation or mobility of FOXO3a in cells expressing activated Akt. These data indicate that the effects of LY294002 on FOXO3a protein mobility in response to IL-3 depend on inactivation of the PI3K/Akt pathway. Taken together, the results suggest that protein levels of both FOXO1 and FOXO3a are regulated in response to the activation of Akt in a proteasome-dependent manner.
The effects on FOXO3a protein mobility suggested that the activation of
endogenous Akt by the IL-3 receptor can influence protein stability. To
further explore whether proteasomal degradation of Akt substrates is
induced at physiologic levels of Akt activation, we examined the
effects of IL-3-induced Akt activation on the expression and
phosphorylation status of tuberin and FOXO3a after the addition of IL-3
to growth factor-deprived cells. IL-3 was added to cells that had been
pretreated for 30 min with vehicle control or epoxomicin. We have
previously demonstrated under these conditions that IL-3 causes a rapid
induction of PI3K-dependent Akt activity that is detectable
within 5 min and persists for more than an hour (14). Total cell
lysates were isolated at several time points and probed in immunoblots
with antisera that recognize Akt phosphorylation sites within tuberin
and FOXO3a. IL-3-stimulated phosphorylation of tuberin and FOXO3a was
maximal at 10 min followed by a decay in phosphorylation and
protein levels over time (Fig.
4A). Treatment of cells with
epoxomicin resulted in the accumulation of phosphorylated forms of both
tuberin and FOXO3a at later time points, suggesting that phosphorylated
tuberin and FOXO3a are targeted for proteasomal degradation after IL-3 withdrawal (Fig. 4A). At later time points, IL-3 stimulation
caused a mild decline in tuberin protein levels that was abrogated by the addition of epoxomicin (compare Fig. 4A, lanes 9 and
10, with lanes 1 and 2). As seen in ALLN-treated
cells, FOXO3a was characterized by heterogeneous mobility at early time
points after IL-3 stimulation, and this persisted in epoxomicin-treated
cells (Figs. 3, B and C, and 4A).
|
To confirm that direct Akt phosphorylation is required for Akt-induced protein degradation, we experimentally introduced tetracycline-inducible constructs of either wild type human FOXO1 or a human FOXO1 in which Akt phosphorylation sites had been mutated to alanine (FOXO1-3A) into FL5.12 cells (17). These cells were then infected with a retrovirus encoding GFP alone or both GFP and myrAkt. GFP-positive cells were isolated by cell sorting and expanded in the presence or absence of doxycycline. In cells expressing wild type FOXO1, expression of myrAkt led to increased levels of phosphorylated Akt and a concomitant decline in the level of FOXO1 protein. In cells expressing FOXO1-3A in which major Akt phosphorylation sites have been mutated, the effect of myrAkt on the proteins levels of the FOXO1-3A protein was blunted compared with the effect of Akt on wild type FOXO1 (Fig. 4B). These data indicate that Akt-induced declines in FOXO protein levels require the presence of Akt phosphorylation sites in the substrate.
The 26 S proteasome degrades proteins that are conjugated to
polyubiquitin chains. Akt-induced degradation of substrates in the
proteasome may be stimulated by an increase in the ubiquitination of
these proteins. To determine whether tuberin ubiquitination is
increased in cells expressing activated Akt, ubiquitinated proteins
were enriched using an affinity matrix consisting of glutathione
S-transferase fused to the ubiquitin-binding UBA domains of
Rad23 (27, 28). Tuberin was enriched among ubiquitinated proteins
isolated from epoxomicin-treated myrAkt cells compared with vector
control cells (cultured in the absence of IL-3), indicating that
increased Akt activity is sufficient to cause an increase in tuberin
ubiquitination (Fig. 5A).
|
To determine whether activation of the endogenous PI3K/Akt pathway by the IL-3 receptor can cause a generalized increase in the ubiquitination of Akt substrates, vector control and myrAkt cells were stimulated with IL-3 in the presence and absence of epoxomicin and LY294002 for 60 min, a time point at which degradation of tuberin and FOXO3a was observed previously (Fig. 4A). Akt substrates were detected using the Akt substrate antiserum in fractions enriched for ubiquitinated proteins using the Rad23 UBA domains (Fig. 5B). In vector control cells, ubiquitinated Akt substrates were detected in lysates from epoxomicin-treated cells but not from cells treated with vehicle control, suggesting that ubiquitinated Akt substrates are processed through the proteasome on stimulation of the endogenous PI3K/Akt pathway with IL-3. The addition of LY294002, a PI3K inhibitor that blocks the activation of Akt by the IL-3 receptor, prevented the accumulation of ubiquitinated Akt substrates in epoxomicin-treated cells, suggesting that activation of Akt was required for ubiquitination of these proteins. Expression of activated Akt-enriched ubiquitinated proteins detected using the Akt substrate antiserum (Fig. 5B). The addition of LY294002 reduced but did not eliminate the detection of Akt substrates among ubiquitinated proteins in myrAkt cells, suggesting that the effect of LY294002 in vector control cells required inactivation of Akt. By combining the data obtained from vector control and myrAkt cells, ubiquitinated Akt substrates can be identified as proteins that are 1) detected in epoxomicin-treated vector control cells, 2) not detected in vector control cells treated with LY294002 and epoxomicin, and 3) detected in myrAkt cells treated with either epoxomicin or LY294002 and epoxomicin. Proteins meeting these criteria are marked with an asterisk (Fig. 5B). An additional potential ubiquitinated Akt substrate was also identified only in lysates from myrAkt cells. These data suggest that a number of proteins are phosphorylated and ubiquitinated in an Akt-dependent manner in response to stimulation with IL-3 or expression of myrAkt, resulting in proteasome-dependent degradation of Akt substrates.
Previous reports have suggested that Akt phosphorylation of substrates can alter their subcellular distribution, induce their association with 14-3-3 proteins, and/or inhibit their catalytic activity (29). The data presented here show that an additional effect of Akt phosphorylation is the ubiquitination and proteasomal degradation of the substrates of Akt. Prolonged expression of myrAkt caused proteasome-dependent declines in tuberin and FOXO protein levels, which were recapitulated to a lesser degree by stimulation of the PI3K/Akt pathway by the IL-3 receptor. Differences in the magnitude of the effects of myrAkt and the IL-3 receptor on tuberin and FOXO protein levels may be a result of the relative levels of Akt activation between the two stimuli, as shown in Fig. 1A. The induction of proteasomal degradation of tuberin and FOXO3a by Akt may serve as prototypic examples of a general mechanism used by Akt in the coordinated regulation of cell growth and survival. This hypothesis is supported by the data presented in Fig. 3A, which indicate that the phosphorylation of a number of Akt substrates is stabilized by the addition of proteasome inhibitors. Furthermore, endogenous levels of Akt are sufficient to cause both ubiquitination and degradation of substrates (Figs. 3B, 4A, and 5B), indicating that these effects can be induced in a physiologic context.
Recent findings show that Akt can control the expression levels of proteins, such as p53, the androgen receptor, and insulin receptor substrate-1 (30-32). The mechanism by which Akt targets substrates such as tuberin and FOXO proteins for ubiquitination is unknown. Akt has been shown to activate the ubiquitin ligase activity of murine double minute-2, and murine double minute-2 activity has been implicated in Akt-stimulated increases in androgen receptor and p53 degradation (30, 31, 33). Alternatively, an E3 ubiquitin ligase may specifically target proteins with phosphorylated residues within Akt substrate motifs in a manner analogous to the regulation of protein stability by ubiquitin ligases capable of binding to proteins phosphorylated by glycogen synthase kinase-3 (34).
The PI3K/Akt pathway plays a critical role in promoting cell growth and
survival downstream of growth factor receptors. Much of the growth and
survival activities of Akt have been attributed to the ability of Akt
to inhibit the function of proteins that mediate cellular atrophy and
programmed cell death. Using tuberin and FOXO3a as examples, we have
shown that Akt targets its substrates for degradation via the
proteasome. We propose that proteasomal degradation of substrates may
therefore represent a central mechanism by which Akt acts to promote
cell growth and survival.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank Dr. Jeff E. DeClue (National Cancer Institute) for the anti-hamartin antibody, Drs. Fred Barr (University of Pennsylvania) and Gabriel Nunez (University of Michigan) for FOXO1 constructs, and colleagues in the Thompson laboratory, particularly Dr. Aimee Edinger and Monica Buzzai, for helpful advice and reagents.
![]() |
FOOTNOTES |
---|
* This work was supported by the Irvington Institute for Immunological Research (to D. R. P.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Abramson Family Cancer
Research Inst., 421 Curie Blvd., Philadelphia, PA 19146. Tel.:
215-746-5515; Fax: 215-746-5511; E-mail: drt@mail.med.upenn.edu.
Published, JBC Papers in Press, January 6, 2003, DOI 10.1074/jbc.M213069200
![]() |
ABBREVIATIONS |
---|
The abbreviations used are: PI3K, phosphatidylinositol 3-kinase; FOXO, forkhead box, subclass O; ALLN, N-acetyl-leucine-leucine-norleucinal; ALLM, N-acetyl-leucine-leucine-methional; IL, interleukin; GFP, green fluorescent protein; myrAkt, myristoylated Akt; UBA, ubiquitin-associated domain.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Conlon, I., and Raff, M. (1999) Cell 96, 235-244[Medline] [Order article via Infotrieve] |
2. | Kozma, S. C., and Thomas, G. (2002) Bioessays 24, 65-71[CrossRef][Medline] [Order article via Infotrieve] |
3. | Bellacosa, A., Testa, J. R., Staal, S. P., and Tsichlis, P. N. (1991) Science 254, 274-277[Medline] [Order article via Infotrieve] |
4. |
Chang, H. W.,
Aoki, M.,
Fruman, D.,
Auger, K. R.,
Bellacosa, A.,
Tsichlis, P. N.,
Cantley, L. C.,
Roberts, T. M.,
and Vogt, P. K.
(1997)
Science
276,
1848-1850 |
5. | Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., Frye, C., Hu, R., Swedlund, B., Teng, D. H., and Tavtigian, S. V. (1997) Nat. Genet. 15, 356-362[Medline] [Order article via Infotrieve] |
6. | Dijkers, P. F., Medema, R. H., Lammers, J. W., Koenderman, L., and Coffer, P. J. (2000) Curr. Biol. 10, 1201-1204[CrossRef][Medline] [Order article via Infotrieve] |
7. | Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., and Greenberg, M. E. (1999) Cell 96, 857-868[Medline] [Order article via Infotrieve] |
8. |
Dijkers, P. F.,
Medema, R. H.,
Pals, C.,
Banerji, L.,
Thomas, N. S.,
Lam, E. W.,
Burgering, B. M.,
Raaijmakers, J. A.,
Lammers, J. W.,
Koenderman, L.,
and Coffer, P. J.
(2000)
Mol. Cell. Biol.
20,
9138-9148 |
9. | Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., and Cantley, L. C. (2002) Mol. Cell 10, 151-162[Medline] [Order article via Infotrieve] |
10. | Gao, X., Zhang, Y., Arrazola, P., Hino, O., Kobayashi, T., Yeung, R. S., Ru, B., and Pan, D. (2002) Nat. Cell Biol. 4, 699-704[CrossRef][Medline] [Order article via Infotrieve] |
11. | Inoki, K., Li, Y., Zhu, T., Wu, J., and Guan, K. L. (2002) Nat. Cell Biol. 4, 648-657[CrossRef][Medline] [Order article via Infotrieve] |
12. | Potter, C. J., Pedraza, L. G., and Xu, T. (2002) Nat. Cell Biol. 4, 658-665[CrossRef][Medline] [Order article via Infotrieve] |
13. | Rathmell, J. C., Vander Heiden, M. G., Harris, M. H., Frauwirth, K. A., and Thompson, C. B. (2000) Mol. Cell 6, 683-692[Medline] [Order article via Infotrieve] |
14. |
Plas, D. R.,
Talapatra, S.,
Edinger, A. L.,
Rathmell, J. C.,
and Thompson, C. B.
(2001)
J. Biol. Chem.
276,
12041-12048 |
15. |
Vander Heiden, M. G.,
Plas, D. R.,
Rathmell, J. C.,
Fox, C. J.,
Harris, M. H.,
and Thompson, C. B.
(2001)
Mol. Cell. Biol.
21,
5899-5912 |
16. | Vander Heiden, M. G., Chandel, N. S., Williamson, E. K., Schumacker, P. T., and Thompson, C. B. (1997) Cell 91, 627-637[CrossRef][Medline] [Order article via Infotrieve] |
17. |
Tang, E. D.,
Nunez, G.,
Barr, F. G.,
and Guan, K. L.
(1999)
J. Biol. Chem.
274,
16741-16746 |
18. | Yaffe, M. B., Leparc, G. G., Lai, J., Obata, T., Volinia, S., and Cantley, L. C. (2001) Nat. Biotechnol. 19, 348-353[CrossRef][Medline] [Order article via Infotrieve] |
19. |
Dan, H. C.,
Sun, M.,
Yang, L.,
Feldman, R. I.,
Sui, X. M.,
Yeung, R. S.,
Halley, D. J.,
Nicosia, S. V.,
Pledger, W. J.,
and Cheng, J. Q.
(2002)
J. Biol. Chem.
277,
35364-35370 |
20. |
Nellist, M.,
van Slegtenhorst, M. A.,
Goedbloed, M.,
van den Ouweland, A. M.,
Halley, D. J.,
and van der Sluijs, P.
(1999)
J. Biol. Chem.
274,
35647-35652 |
21. | Benvenuto, G., Li, S., Brown, S. J., Braverman, R., Vass, W. C., Cheadle, J. P., Halley, D. J., Sampson, J. R., Wienecke, R., and DeClue, J. E. (2000) Oncogene 19, 6306-6316[CrossRef][Medline] [Order article via Infotrieve] |
22. | Potter, C. J., Huang, H., and Xu, T. (2001) Cell 105, 357-368[Medline] [Order article via Infotrieve] |
23. | Tapon, N., Ito, N., Dickson, B. J., Treisman, J. E., and Hariharan, I. K. (2001) Cell 105, 345-355[Medline] [Order article via Infotrieve] |
24. | Deshaies, R. J., and Ferrell, J. E., Jr. (2001) Cell 107, 819-822[Medline] [Order article via Infotrieve] |
25. | Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., and Goldberg, A. L. (1994) Cell 78, 761-771[Medline] [Order article via Infotrieve] |
26. | Kisselev, A. F., and Goldberg, A. L. (2001) Chem. Biol. 8, 739-758[CrossRef][Medline] [Order article via Infotrieve] |
27. |
Chen, L.,
Shinde, U.,
Ortolan, T. G.,
and Madura, K.
(2001)
EMBO Rep.
2,
933-938 |
28. | Wilkinson, C. R., Seeger, M., Hartmann-Petersen, R., Stone, M., Wallace, M., Semple, C., and Gordon, C. (2001) Nat. Cell Biol. 3, 939-943[CrossRef][Medline] [Order article via Infotrieve] |
29. | Kandel, E. S., and Hay, N. (1999) Exp. Cell Res. 253, 210-229[CrossRef][Medline] [Order article via Infotrieve] |
30. | Gottlieb, T. M., Leal, J. F., Seger, R., Taya, Y., and Oren, M. (2002) Oncogene 21, 1299-1303[CrossRef][Medline] [Order article via Infotrieve] |
31. |
Lin, H. K.,
Wang, L.,
Hu, Y. C.,
Altuwaijri, S.,
and Chang, C.
(2002)
EMBO J.
21,
4037-4048 |
32. |
Zhande, R.,
Mitchell, J. J.,
Wu, J.,
and Sun, X. J.
(2002)
Mol. Cell. Biol.
22,
1016-1026 |
33. | Zhou, B. P., Liao, Y., Xia, W., Zou, Y., Spohn, B., and Hung, M. C. (2001) Nat. Cell Biol. 3, 973-982[CrossRef][Medline] [Order article via Infotrieve] |
34. |
Aberle, H.,
Bauer, A.,
Stappert, J.,
Kispert, A.,
and Kemler, R.
(1997)
EMBO J.
16,
3797-3804 |